VIGL — Vigil Neuroscience Cashflow Statement
0.000.00%
Last trade - 00:00- $375.71m
- $288.60m
Annual cashflow statement for Vigil Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.5 | -43.3 | -68.3 | -82.6 | -84.3 |
| Depreciation | |||||
| Non-Cash Items | 22.5 | 3.27 | 6.41 | 8.78 | 9.96 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.85 | 0.642 | -3.33 | 3.1 | 22.6 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -5.18 | -39.3 | -65.1 | -70.4 | -51.2 |
| Capital Expenditures | 0 | -0.204 | -0.921 | -0.674 | -0.005 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.5 | 0 | — | -64.5 | 8.77 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.5 | -0.204 | -0.921 | -65.1 | 8.76 |
| Financing Cash Flow Items | 5 | -1.89 | 0 | — | 9.54 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 29.8 | 108 | 161 | 0.888 | 29.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 24.2 | 68.2 | 95.2 | -135 | -13 |